Implied Volatility

Showing 985 articles
Business

Minerals 260's Valuation in Focus After Bullabulling Gold Resource Boost to 4.5M Ounces

Minerals 260 (ASX:MI6) has significantly upgraded the resource estimate at its flagship Bullabulling gold project to 4.5 million ounces, sparking renewed investor interest. Despite recent share price volatility, the long-term outlook appears buoyed by upcoming study milestones and a substantial intrinsic value gap, raising questions about whether the market is undervaluing its potential.

Business

Medical Properties Trust Sees Surge in Options Bets Ahead of Earnings, Spotlight on Turnaround Hopes

Ahead of its February 26 earnings report, Medical Properties Trust (NYSE: MPW) is witnessing a notable spike in options activity, with call volume soaring to roughly five times its usual level. This surge in speculative interest comes as the healthcare REIT's shares hover around $5.05, showing recent momentum but still grappling with a challenging multi-year performance. Analysts are divided on whether the stock's current price reflects lingering past troubles or is beginning to price in a potential recovery narrative.

Business

Carnival Stock: A Deep Value Play After Debt Pivot and Travel Rebound?

Carnival Corporation's shares have surged over three years, yet a detailed financial analysis suggests the cruise giant may still be trading at a significant discount. As the industry navigates post-pandemic recovery and debt reduction, investors are weighing if the current price reflects underlying value or lingering risks.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.